Reviewed July 28, 2026
Is Emideltide (DSIP) Legal? FDA Status and Licensed Care Options
The advisory committee did not recommend this compound. Here is exactly what that means.
The short answer
- FDA status
- Not an FDA-approved drug product
- July 2026 vote
- Advisory committee did not recommend for the 503A bulks list
- Reviewed for
- Opioid withdrawal, chronic insomnia, and narcolepsy
- Prescriber
- Required. Available only through a licensed clinician.
The committee did not recommend this compound for the 503A bulks list. This is a regulatory recommendation about compounding eligibility - not a safety finding, and not a statement that the compound is banned.
Why “is it legal” has no yes-or-no answer
For peptides, access is not a single switch. It depends on the FDA status of the substance, whether a compounding pathway applies, what your state’s pharmacy and medical boards permit, and whether a licensed clinician has evaluated you and written a prescription. Any source giving you a flat yes or no is skipping at least three of those.
Emideltide, usually sold and discussed as DSIP or Delta Sleep-Inducing Peptide, is the one compound of the seven that the advisory committee did not recommend. That makes it the most likely to be misdescribed in both directions - either quietly bundled in with the other six, or overstated as having been outlawed.
What the advisory committee actually reviewed
The committee reviewed Emideltide in the context of opioid withdrawal, chronic insomnia, and narcolepsy, and did not recommend it for the 503A bulks list. Read that precisely: it is a recommendation about compounding eligibility. It is not a safety finding, not a determination that the compound is harmful, and not a statement that it has been prohibited.
Sleep-peptide marketing does not mean the committee supported access.
What a committee recommendation is — and is not
The Pharmacy Compounding Advisory Committee advises the FDA. Its recommendations can shape what the agency does next, but the FDA is not required to follow them, and a recommendation is not a drug approval, a safety finding, a prescription, or proof that any clinic can offer something today. The FDA meeting record and the 503A bulk drug substances page are the authoritative sources.
Questions people ask
Was DSIP banned by the FDA?
No. The advisory committee did not recommend it for the 503A bulks list. That is a recommendation about compounding eligibility, not a prohibition, and not a safety finding.
Why was Emideltide treated differently from the other six?
The committee reviewed each substance separately and reached a different recommendation for this one. The FDA's meeting record is the authoritative source for the reasoning.
Sleep products mention DSIP. Does the vote support that?
No. Sleep-peptide marketing does not mean the committee supported access. This is the compound the committee did not recommend.
Does this decision affect the other six peptides?
No. Each substance was considered on its own. The other six were recommended to continue in the process.
Finding licensed care
If you want to talk to someone who can actually evaluate your situation, start with a licensed clinic. We list clinics by city and publish what we verified about each one, with the date we verified it.
Clinics we list: San Antonio, TX, Seattle, WA, Phoenix, AZ, Scottsdale, AZ